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Inﬂuence of transjugular intrahepatic portosystemic shunt in patients awaiting
orthotopic liver transplant on post-transplant outcome
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Background: This study was conducted to evaluate the safety and efﬁcacy of transjugular intrahepatic portosystemic shunts (TIPS) in patients awaiting
orthotopic liver transplantation (OLT) and to identify factors affecting post-transplant survival.
Methods: Consecutive patients who underwent TIPS followed by OLT between January 1991 and December 2008 were included in the study. The Kaplan–
Meier method was used for survival analysis. Survival curves were compared using the log rank test.
Results: A total of 129 patients underwent TIPS followed by OLT and were included in our study. The mean age of the group was 54.67 years (SD, 11.45;
range, 16–74 years). The mean duration of follow-up was 2.3 years (range, 1 day–15 years). The mean duration between ﬁrst TIPS placement and OLT was
1.5 years (range, 0.1–13.4 years). The post-transplant survival rates at 1 month, 1 year, 3 years, 5 years, and 10 years were 98%, 82%, 75%, 69%, and 43%,
respectively. The technical success rate of the OLT was 100% in patients who had undergone pre-transplant TIPS. The post-transplant survival was not
inﬂuenced by pre-TIPS portosystemic gradient (P ¼ 0.295) or the drop in pressure after TIPS (P ¼ 0.423). On multivariate analysis, hepatitis C virus
positivity [P ¼ 0.001; hazard ratio ¼ 2.50 (1.47–4.25)] and Model for End-stage Liver Disease score [P ¼ 0.015; hazard ratio ¼ 2.45 (1.19–5.02)] were found
to be signiﬁcant predictors of post-transplant long-term survival. The incidence of post-TIPS complications was 32.6% (42/129). The most common
complication was procedure-related bleeding (8.5%) followed by hepatic encephalopathy (7.0%).
Conclusion: Post-transplant survival in patients who undergo TIPS before OLT is excellent. Higher Model for End-stage Liver Disease scores and hepatitis C
positivity result in worse post-transplant survival.
Copyright  2012, Society of Gastrointestinal Intervention. Published by Elsevier. All rights reserved.
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In patients with liver failure, orthotopic liver transplant (OLT)
remains the only deﬁnitive treatment for end-stage disease.1
Currently, there are more than 15,000 patients awaiting liver
transplant in the United States.2,3 From 2004 to 2008, the number
of patients receiving transplants increased roughly 2% from 6171 to
6318, while new additions to the transplant list grew 4% from
10,170 to 10,608.2 While the demand for liver transplantation
remains high, the number of available livers has remained fairly
constant despite efforts to expand criteria for donations.3 The pre-
transplant course is often accompanied by complications of
decompensated liver disease and portal hypertension like ascites
and gastrointestinal bleeding. Even though we attempt to optimize
the use of the donor organ pool, we continue to have an absolute1Division of Interventional Radiology and Image Guided Medicine, Emory University Hospit
2Division of Digestive Diseases, Emory University School of Medicine, Atlanta, GA, USA
Received 16 July 2012; Revised 13 August 2012; Accepted 16 August 2012
* Corresponding author. 1364 Clifton Road NE, Suite AG-05, Interventional Radiology an
USA.
E-mail address: kevin.kim@emory.edu (H.S. Kim).
2213-1795/$ – see front matter Copyright  2012, Society of Gastrointestinal Interventi
http://dx.doi.org/10.1016/j.gii.2012.08.009organ shortage with increased waiting times on the transplant list
resulting in pre-transplant complications.2,4
Transjugular intrahepatic portal systemic shunt (TIPS) is
currently the only nonsurgical method of creating a portal systemic
shunt and is an effective tool in the symptomatic treatment of
complications of advanced liver disease.5 TIPS have proven to be
effective in controlling both variceal bleeding and refractory
ascites.6,7 The creation of TIPS in patients awaiting OLT has been
described byseveral researchgroups.8–14 It has been shown, in small
case series and case controls studies, to decrease the symptom-
atology of patients awaiting liver transplant. In these patients, the
TIPS procedure has been used as a bridging therapy to allow them to
remain on the transplant list longer and reduce patient dropout.
Our goal was to evaluate the safety and efﬁcacy of the TIPS
in patients awaiting OLT and to identify factors affectingal, Atlanta, GA, USA
d Image Guided Medicine, Emory University School of Medicine, Atlanta, GA 30322,
on. Published by Elsevier. All rights reserved.
Table 1 Clinical and Demographic Characteristics of Study Group
Factor Categories N (%)
Age < 60 y 104 (80.6%)
> 61 y 25 (19.4%)
Sex Male 88 (68.2%)
Female 41 (31.8%)
Race Caucasian 112 (86.8%)
African American 12 (9.3%)
Other 5 (3.9%)
Etiology HCV 49 (38%)
HBV 5 (3.9%)
ALD 26 (20.2%)
Cryptogenic 16 (12.4%)
Others 33 (25.5%)
Indication GI bleed 45 (34.8%)
Ascites 69 (53.5%)
Hydrothorax 14 (10.9%)
HRS 1 (0.8%)
Indication for TIPS Elective 122 (94.6%)
Emergent 7 (5.4%)
Type of TIPS stent Covered 41 (31.8%)
Uncovered 88 (68.2%)
Size of stent < 10 mm 21 (16.3%)
> 12 mm 108 (83.7%)
ALD, Alcoholic liver disease; HBV, hepatitis B virus; HCV, hepatitis C virus; HRS,
hepatorenal syndrome; TIPS, transjugular intrahepatic portosystemic shunt.
Table 2 Pre-transplant Continuous Variables
Variables Mean Range
Pre TIPS portosystemic gradient 17.56 6–70
Post TIPS portosystemic gradient 5.84 0–16
Pre TIPS creatinine 1.29 0.5–3.8
Pre TIPS Bilirubin 3.98 0.3–36.3
Pre TIPS INR 1.71 1.01–7.89
Pre TIPS albumin 2.45 1.0–4.0
Pre TIPS Platelets 98 24–381
Pre TIPS Alkaline Phosphatase 146 32–703
Pre TIPS AST 68 13–210
Pre TIPS ALT 45 7–175
AST, aspartate transaminase; ALT, alanine aminotransferase; INR, international
nationalized ratio; TIPS, transjugular intrahepatic portosystemic shunt.
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patients receiving TIPS before OLT.
Methods
Patient selection
Consecutive patients who underwent TIPS creation followed by
OLT between January 1991 and December 2008 were included in
the study after approval from the institutional review board.
Patients were included solely if they underwent TIPS procedure
and subsequently received OLT.
Data collection
Clinical, laboratory, and procedure-related data was collected
and reviewed retrospectively through chart review. Clinical
features recorded were age, gender, race, etiology of cirrhosis, and
transplant history. Pre- and post-TIPS laboratory values recorded
were serum bilirubin, creatinine, albumin, aspartate transaminase,
alanine aminotransferase, alkaline phosphatase, and international
normalized ratio. Model for End-stage Liver Disease (MELD) scores
were then calculated from the laboratory values. The following
procedure data were collected: date of TIPS, pre- and post-TIPS
portosystemic pressure gradient, number of revisions, whether
the procedure was emergent or elective, patency rates, type of
stent, and size of TIPS stent.
Outcome
Patients were followed up until death, review date, or until they
were lost to follow-up. Procedure-related complications and 30-
day mortality after TIPS were also recorded. Complications and
whether the patient needed repeat TIPS were recorded. Encepha-
lopathy was attributed as a complication of TIPS if it appeared or
worsened after TIPS creation. Moderate and severe encephalopathy
has been reported.
Statistics
Chi square test was used to compare categorical variables and
Student t-test was used to compare continuous variables. Survival
was calculated from the date of OLT to date of death. Kaplan–Meier
method was used for survival analysis. Survival curves were
compared using the log rank test. Cox proportional hazardsmethod
was used for multivariate analysis, and data were entered using
backward Wald. Only factors found to be signiﬁcant on univariate
analysis were included in the model for multivariate analysis. All
statistical analyses were performed using SPSS The software SPSS
Graduate version 16.0 (SPSS Inc., Chicago, IL). A P value of 0.05 or
less was considered statistically signiﬁcant.
Results
A total of 129 patients underwent TIPS followed by OLT and
were included in our study. The mean age of the group was 54.67
years (SD, 11.45; range, 16–74 years). The mean duration of follow-
up was 2.3 years (range, 1 day–15 years). The demographic, clinical,
and laboratory data of the group area are described in Tables 1
and 2.
The mean duration between ﬁrst TIPS placement and OLT was
1.5 years (range, 0.1–13.4 years). The post-transplant survival rates
at 1month,1 year, 3 years, 5 years, and 10 years were 98%, 82%, 75%,
69%, and 43%, respectively. The long-term median post-transplant
survival in patients who underwent transplant after TIPS was 8.7years (95% CI, 7.3–10.2). The technical success rate of the OLT was
100% in the patients who had undergone pre-transplant TIPS. The
mean pre-TIPS portosystemic gradient was 17.56 (range, 6–70), and
the mean drop in portosystemic gradient after TIPS was 11.73
(range, 0–57). The post-transplant survival was not inﬂuenced by
pre-TIPS portosystemic gradient (P ¼ 0.295) or the drop in pressure
after TIPS (P ¼ 0.423).
Factors affecting post-transplant survival were compared on
univariate analysis (Table 3). Hepatitis C virus (HCV) positivity
(P ¼ 0.001) and high MELD scores (P ¼ 0.018) were found to be
associated with poorer post-transplant survival in patients who
underwent TIPS (Figs. 1 and 2). The 1-year survival in HCV negative
recipients was 84%, and in HCV positive recipients it was 75%. Age,
sex, race, etiology of cirrhosis, indication for TIPS, and timing of TIPS
were not statistical predictors of post-transplant survival. On
multivariate analysis, both HCV positivity [P ¼ 0.001; hazard ratio
2.50 (95% CI, 1.47–4.25)] and MELD score [P ¼ 0.015; hazard ratio
2.45 (95% CI, 1.19–5.02)] were found to be signiﬁcant predictors of
post-transplant long-term survival.
In our study, we found that 23% of the patients developed
stenosis of the TIPS and required restenting before OLT. The inci-
dence of post-TIPS complications was 29.4% (38/129). The most
common complication was procedure-related bleeding (8.5%) fol-
lowed by hepatic encephalopathy (7.0%). The incidence of other
complications was as follows: fever/infection 6.2%, pulmonary
Table 3 Factors Affecting Post-transplant Survival
Factor Categories N (%) 1 y survival rate 5 y survival rate P
Age < 60 y 104 (80.6%) 79% 68% 0.727
> 61 y 25 (19.4%) 88% 76%
Sex Male 88 (68.2%) 80% 66% 0.543
Female 41 (31.8%) 83% 72%
Race Caucasian 112 (86.8%) 81% 71% 0.512
African American 12 (9.3%) 83% 75%
Other 5 (3.9%) 67% 67%
Etiology HCVa þve 49 (38%) 75% 60% 0.001
HCVa ve 89 (62%) 84% 76%
Indication GIb bleed 45 (34.8%) 88% 80% 0.094
Ascites 69 (53.5%) 76% 65%
Hydrothorax 14 (10.9%) 78% 71%
Timing Elective 122 (94.6%) 80% 70% 0.298
Emergent 7 (5.4%) 85% 67%
MELDc score < 24 113 (87.5%) 80% 73% 0.018
> 25 16 (12.5%) 69% 43%
HCV, hepatitis C virus; GI, gastrointestinal; MELD, model for end stage liver disease.
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acute renal failure 0.8%.Discussion
Our data on survival rates show adequate post-transplant
survival with 1-, 3-, and 5-year rates of 82%, 75%, and 69%,
respectively. This information was very consistent with nationally
reported data on post-transplant survival.2 In a recent case control
study by Guerrini et al,9 survival rates were similarly reported at
91.7%, 85%, and 81.7%, for 1, 3, and 5 years post-transplant,
respectively, in patients who received pre-transplant TIPS.
Although there was no long-term survival beneﬁt, they reported
seeing a decrease in early mortality in patients receiving TIPS
compared to those not receiving TIPS. It has been hypothesized that
the beneﬁt of TIPS is related to the reduction of collateralization
around the newly transplanted liver, increasing the available blood
ﬂow, and improving liver function, which may help increase short-
term survival.9 However, multiple additional authors have consis-
tently shown that TIPS does not affect either short- or long-termFig. 1. Long-term post-transplant survival in patients with hepatitis C virus (HCV)
positivity was worse than those patients who were HCV negative.outcome8,11,15,16 So the proposed mechanism most likely has less
of an effect on short-term survival and no effect on long-term
survival. Additionally, it would follow that decreased gradient
pressures lead to decreased collateralization. In our study, neither
the initial nor the post-TIPS portosystemic gradient proved to have
any prognostic value in determining the survival after OLT. If there
was some beneﬁt to decreasing collateralization of blood ﬂow
around the liver, one would expect that decreased gradient pres-
sures would correlate with better outcomes, which we did not ﬁnd.
Together, these studies, including ours, suggest that TIPS does not
increase or decrease mortality in the post-transplant period but
most likely improves overall survival, as patients who would
otherwise have fallen off the transplant list were effectively bridged
to liver transplant.8,11,15,16
In our study, we found the main complication of the TIPS
procedure to be refractory hepatic encephalopathy at 7.5%. Pub-
lished literature reports an overall rate of post-shunt encephalop-
athy in 46% of cases5 with medically refractory cases at 5% of
patients.17 The exact pathophysiology of post-shunt encephalop-
athy remains somewhat poorly understood but does seem to beFig. 2. Long-term post-transplant survival in patients with higher MELD (Model for
End-stage Liver Disease) score was worse.
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dramatically increases with shunt creation. It has been reported by
Wroblewski et al that a two-stage TIPS proceduremay be beneﬁcial
for patients who are encephalopathic pre-procedure and may
decrease the development of post-shunt encephalopathy creating
a more gradually change in the portal systemic blood ﬂow.18
Prognostic indicators for encephalopathy development continue
to remain poorly deﬁned and need to be investigated.
Despite the successful use of TIPS in bridging patients
to transplant, many authors have continued to suggest that TIPS
may hinder the actual transplant procedure through misplace-
ment of the shunt stents in either the suprahepatic inferior vena
cava or the portal vein.14,19,20 In our study, all patients were
successfully transplanted despite previous TIPS placement. In our
experience, this tends to suggest that even slight misplacement of
stent is easily corrected during the transplant surgery. However, it
remains important that the TIPS stent is properly placed which
does require the expertise of an experienced interventionalist.
In our study, one of the more signiﬁcant prognostic factors was
the presence of hepatitis C, which appears to be a strong indicator
of poor survival post-transplant. In our population, we noted that
38% of our patients presented with hepatitis C as their underlying
etiology of liver failure and had a 1-year survival rate of 75%. It has
been previously shown that hepatitis C is indeed one of the largest
etiologies of liver failure requiring transplant and also carries the
highest mortality rates outside of fulminant failure and malig-
nancy.1 This is most likely due to high rates of reinfection of the
donor liver with the HCV, as reported in the literature.21 and it is
not surprising that despite TIPS procedure, these patients still fare
poorly.
The MELD score was designed in the late 1990s as a better
predictor of short-term survival in the pre-transplant candidate.22
Since that time it has also been shown by Habib et al,23 in
a study of 1472 patients, that MELD scores are also a predictor of
post-transplant survival, but this remains a less powerful indicator
than its primary use as an indicator of pre-transplant mortality.
Although pre-transplant MELD score have been shown to be
somewhat predictive of post-transplant survival,23 it remained to
be seen whether MELD score has the same predictive power in
patients who receive pre-transplant TIPS. We show that this is
indeed the case as a patient’s pre-TIPSMELD scorewas predictive of
outcome after transplant.
Another complication of the TIPS procedure is stent stenosis/
thrombosis and the need for restenting before transplant.24,25 In
the literature, the frequency of patients undergoing TIPS revision
within the ﬁrst, second, and third years after TIPS placement was
67.5%, 38.0%, and 24.4%, respectively.24 In our study, we found that
23% of patient required restenting before OLT. Because in our
population, patients were receiving TIPS as a bridge to deﬁnitive
therapy, thrombosis rates overall were less common as the reduced
time to deﬁnitive therapy limits thrombosis development.
In general, retrospective study designs suffer from numerous
limitations. Of note, in our selection criteria we recorded patients
who both received TIPS and had subsequent transplant; it is
possible that by doing this we eliminated those with worse prog-
nosis that were either removed from the transplant wait list or died
before transplantation. However, our data still represent a large
case series exploring the prognostic factors that affect post-
transplant survival in patients receiving TIPS before transplant.
Our data are consistent with previous reports on the success of TIPS
in pre-transplant patients; however, there is need for prospective
studies to conclusively determine the beneﬁt of pre-transplant TIPS
procedure on post-transplant survival.
To conclude, post-transplant survival in patients who undergo
TIPS before OLT is excellent. Higher MELD scores and the presenceof hepatitis C are associated with poor post-transplant survival.
This study demonstrates the efﬁcacy and safety utilizing the TIPS
procedure in helping to ameliorate complications of portal hyper-
tension in the pre-transplant period in large case series. With
increasing utilization of liver for transplant and stagnation in
growth of available livers, there are signiﬁcant wait times until
transplantation, and in those patients with refractory complica-
tions, TIPS serves a vital role in bridging patients until suitable
organs become available.
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